These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

436 related articles for article (PubMed ID: 14126805)

  • 41. [Use of blood substitutes in treating shock].
    Koziner VB
    Probl Gematol Pereliv Krovi; 1972 Nov; 17(11):3-8. PubMed ID: 4584751
    [No Abstract]   [Full Text] [Related]  

  • 42. EFFECT OF HYPOTHERMIA ON RED CELL VOLUMES.
    CHANG CB; SHOEMAKER WC
    J Thorac Cardiovasc Surg; 1963 Jul; 46():117-24. PubMed ID: 14044158
    [No Abstract]   [Full Text] [Related]  

  • 43. [ACTION ON THE CIRCULATION OF A NEW PLASMA SUBSTITUTE MADE UP OF POLYMERIZED GELATIN BREAKDOWN PRODUCTS (HEMAGEL)].
    PANNACCIULLI E; SERRA GC
    Minerva Anestesiol; 1963 Sep; 29():369-72. PubMed ID: 14093112
    [No Abstract]   [Full Text] [Related]  

  • 44. [On the problem of plasma substitutes. Conclusion].
    Lundsgaard-Hansen P
    Helv Chir Acta; 1967 Dec; 34(6):566-8. PubMed ID: 5587955
    [No Abstract]   [Full Text] [Related]  

  • 45. [Effects of dextran, gelatine and homologous plasma on circulation in shock caused by severe anemia in the dog].
    Dietze W; Rentrop P; Schmidt HD; Schmier J
    Prakt Anaesth; 1976 Apr; 11(2):59-68. PubMed ID: 959132
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Indications and contraindications for plasma substitutes in operative medicine].
    Simon J; Racenberg E
    Anasth Intensivther Notfallmed; 1981 Apr; 16(2):83-8. PubMed ID: 6167174
    [No Abstract]   [Full Text] [Related]  

  • 47. [ON THE PROLONGATION OF THE PERIOD OF REVERSIBLE CHANGES UNDER CEREBRAL HYPOTHERMIA IN SEVERE BLOOD LOSS].
    PETROV IR; GERBUT KA
    Vestn Khir Im I I Grek; 1964 Nov; 93():3-9. PubMed ID: 14319696
    [No Abstract]   [Full Text] [Related]  

  • 48. [CHANGES IN PLASMA AND ERYTHROCYTE VOLUMES AFTER PERFUSION OF 1 LITER OF RHEOMACRODEX, 1 LITER OF HAEMACCEL AND TRANSFUSION OF 500 ML OF ERYTHROCYTES].
    SCHNEIDER KW; BECKER G; NOWICKI L
    Cah Anesthesiol; 1964; 12():303-18. PubMed ID: 14192966
    [No Abstract]   [Full Text] [Related]  

  • 49. Hypovolemic shock.
    Boyan CP
    Anesth Analg; 1967; 46(6):746-50. PubMed ID: 6070166
    [No Abstract]   [Full Text] [Related]  

  • 50. [Experimental studies on the effectiveness of various volume expanding substances in the treatment of hemorrhagic shock].
    Lutz H; Just OH
    Klin Med Osterr Z Wiss Prakt Med; 1967; 22(3):131-4. PubMed ID: 5632099
    [No Abstract]   [Full Text] [Related]  

  • 51. [Prolonged treatment with plasma substitutes].
    Lutz H; Peter K
    Z Gesamte Exp Med Einschl Exp Chir; 1971; 154(3):224-34. PubMed ID: 5559795
    [No Abstract]   [Full Text] [Related]  

  • 52. TRIAL TO DIMINISH THE BLOOD VOLUME FOR PRIMING OF THE SPINNING DISC OXYGENATOR.
    BJOERK VO; HELLSTROEM G; NORDLUND S
    Ann Chir Gynaecol Fenn; 1963; 52():521-5. PubMed ID: 14083853
    [No Abstract]   [Full Text] [Related]  

  • 53. [Plasma substitutes in first aid and their most important adverse effects].
    Grünewald G; Gaida H; Bucklitsch W
    Beitr Orthop Traumatol; 1969 Jun; 16(6):339-44. PubMed ID: 5376049
    [No Abstract]   [Full Text] [Related]  

  • 54. EFFECT OF LOW MOLECULAR WEIGHT DEXTRAN ON SURVIVAL FOLLOWING HEMORRHAGIC SHOCK.
    GREENFIELD L; BLALOCK A
    Surgery; 1964 May; 55():684-6. PubMed ID: 14146528
    [No Abstract]   [Full Text] [Related]  

  • 55. Therapeutic effect of gelatin plasma substitutes in experimental shock.
    Broghammer H
    Bibl Haematol; 1969; 33():223-31. PubMed ID: 5383992
    [No Abstract]   [Full Text] [Related]  

  • 56. Responses to hemorrhage replaced by lactated Ringer solution.
    Boba A
    Acta Anaesthesiol Scand Suppl; 1968; 31():5-76. PubMed ID: 4952984
    [No Abstract]   [Full Text] [Related]  

  • 57. Modified fluid gelatin as a plasma substitute.
    Lundsgaard-Hansen P; Tschirren B
    Prog Clin Biol Res; 1978; 19():227-57. PubMed ID: 351631
    [No Abstract]   [Full Text] [Related]  

  • 58. [MACROMOLECULAR INJECTABLE SUBSTANCES].
    WEIL GP
    J Pharm Belg; 1963; 18():445-82. PubMed ID: 14086853
    [No Abstract]   [Full Text] [Related]  

  • 59. Scope and limitations of therapy with plasma substitutes: differential indication for substitutes, blood preparations and electrolyte solutions.
    Reissigl H
    Bibl Haematol; 1969; 33():32-54. PubMed ID: 4914355
    [No Abstract]   [Full Text] [Related]  

  • 60. Reversal of postoligemic shock in the cat by hypervenobaric massive fluid therapy.
    Brand ED; Suh TK; Avery MC
    Am J Physiol; 1966 Nov; 211(5):1232-40. PubMed ID: 5924047
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.